111635-19-9

Usage

Uses

Used in Pharmaceutical Industry:
(6aR)-6,10-dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol is used as a potential therapeutic agent for [application reason] due to its structural resemblance to clozapine and its potential interactions with neurotransmitter receptors in the brain.
Used in Research and Development:
In the field of neuroscience and pharmacology, (6aR)-6,10-dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol serves as a valuable compound for [application type] to study its effects on the central nervous system and to explore its potential as a novel therapeutic agent for various neurological disorders.

Upstream product

• 142835-98-1 (-)-3-deoxy-3-methylmorphine 
• 142835-97-0 (-)-(R)-11-methoxy-10-methylaporphine 
• 111635-20-2 (R)-11-Hydroxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10-carbaldehyde 
• 143051-84-7 (-)-(R)-11-methoxy-10-methylaporphine hydrochloride 
• 52-26-6 morphine hydrochloride 
• 142835-95-8 (-)-3-O-<(trifluoromethyl)sulfonyl>morphine 
• 88247-20-5 (-)-11-Hydroxyaporphine 
• 83207-97-0 (R)-(-)-11-methoxyaporphine hydrochloride 
• 150542-80-6 Trifluoro-methanesulfonic acid (R)-11-hydroxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl ester 
• 142835-96-9 (-)-(R)-11-methoxy-10-<<(trifluoromethyl)sulfonyl>oxy>aporphine 
• 57-27-2 MORPHIN 

Relevant academic research and scientific papers

R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands

Several N-substituted-11-hydroxy-10-hydroxymethyl- and 11-hydroxy-10-methylaporphines were synthesized and their binding affinities at dopamine D1 and D2 receptors and serotonin 5-HT1A and 5-HT2A receptors in rat forebrain tissue were evaluated. Tested compounds displayed moderate to high affinity to 5-HT1A receptors but low affinity to D1 and D2 receptors. The most potent novel 5-HT1A agent was R-(-)-N-methyl-10-hydroxymethyl-11-hydroxyaporphine.

(R)-(-)-10-Methyl-11-hydroxyaporphine: A Highly Selective Serotonergic Agonist

Prior work in these laboratories identified (+/-)-5-hydroxy-6-methyl-2-(di-n-propylamino)tetralin as a dopaminergic agonist prodrug.The ortho methyl hydroxy aromatic substitution pattern in this molecule has now been incorporated into the aporphine ring s

(R)-11-Hydroxy- and (R)-11-Hydroxy-10-methylaporphine: Synthesis, Pharmacology, and Modelling of D2A and 5-HT1A Receptor Interactions

(R)-11-Hydroxyaporphine (2) and (R)-11-hydroxy-10-methylaporphine (3) were synthesized from natural morphine by using new, short, and efficent synthetic sequences.The dopaminergic and serotonergic effects of 2 and 3 were evaluated by use of in vitro and in vivo test systems.The results indicate that 3 is a potent, selective, and efficacious 5-HT1A receptor agonist.In contrast, 2 is a partial 5-HT1A receptor agonist of low potency which has affinity also for central D1 and D2A receptors.The differences in pharmacological profiles were rationalized by modeling of ligand-receptor interactions using homology-based receptor models of the 5-HT1A and D2A receptor binding site.The selective and pronounced serotonergic effects of 3 appear to be due to the C10-methyl group, which is accommodated by a lipophilic pocket in the 5-HT1A receptor.In contrast, the C10-methyl group of 3 is not accommodated by the binding site model of the D2A receptor.

Facile Syntheses of Aporphine Derivatives

New and efficient synthetic routes, utilizing palladium-catalysed reactions, provide (R)-11-hydroxy-10-methylaporphine 2 and (R)-11-hydroxyaporphine 3 from natural morphine 4.